Oxidative stress in schizophrenia: A case-control study on the effects on social cognition and neurocognition

BMC Psychiatry

Volumn 14, Issue 1, 2014, Pages

  Gonzalez Liencres, Cristina ^a   Tas, Cumhur ^a,b   Brown, Elliot C ^a,c   Erdin, Soner ^d   Onur, Ece ^d   Cubukcoglu, Zeynep ^d   Aydemir, Omer ^d   Esen Danaci, Aysen ^d   Brüne, Martin ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b USKUDAR UNIVERSITY   (Turkey)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d CELAL BAYAR UNIVERSITY   (Turkey)

Author keywords

Emotion recognition; Executive functioning; Glutathione; Malondialdehyde; Neurotrophin 4; Neurotrophin 5; Nitric oxide; Reactive oxygen species; Superoxide dismutase; Theory of mind; Working memory

Indexed keywords

GLUTATHIONE; HOMOCYSTEINE; MALONALDEHYDE; NEUROTROPHIN 4; NITRIC OXIDE; SUPEROXIDE DISMUTASE; ANTIOXIDANT; BIOLOGICAL MARKER; NERVE GROWTH FACTOR; REACTIVE OXYGEN METABOLITE;

ADULT; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; COGNITION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME BLOOD LEVEL; EXECUTIVE FUNCTION; FEMALE; HUMAN; MALE; NEUROCOGNITION; OXIDATIVE STRESS; POSITIVE AND NEGATIVE SYNDROME SCALE; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA; SOCIAL COGNITION; SYMPTOMATOLOGY; ADOLESCENT; BLOOD; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY; SOCIAL BEHAVIOR; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIOXIDANTS; BIOMARKERS; CASE-CONTROL STUDIES; COGNITION; FEMALE; GLUTATHIONE; HOMOCYSTEINE; HUMANS; MALE; MALONDIALDEHYDE; MIDDLE AGED; NERVE GROWTH FACTORS; NITRIC OXIDE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOCIAL BEHAVIOR; SUPEROXIDE DISMUTASE; YOUNG ADULT;

EID: 84910097611     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/s12888-014-0268-x     Document Type: Article

References (75)

1. Addington J, Addington D. Neurocognitive and social functioning in schizophrenia. Schizophr Bull 1999, 25:173-182. 10.1093/oxfordjournals.schbul.a033363, 10098920.
2. L Waddington J, F Buckley P, Scully PJ, Lane A, O'Callaghan E, Larkin C. Course of psychopathology, cognition and neurobiological abnormality in schizophrenia: developmental origins and amelioration by antipsychotics?. J Psychiatr Res 1998, 32:179-189. 10.1016/S0022-3956(97)00012-5.
3. Xu M-Q, Sun W-S, Liu B-X, Feng G-Y, Yu L, Yang L, He G, Sham P, Susser E, St Clair D, He L. Prenatal malnutrition and adult schizophrenia: further evidence from the 1959-1961 Chinese famine. Schizophr Bull 2009, 35:568-576. 10.1093/schbul/sbn168, 19155344.
4. Hambrecht M, Häfner H. Substance abuse and the onset of schizophrenia. Biol Psychiatry 1996, 40:1155-1163. 10.1016/S0006-3223(95)00609-5, 8931919.
5. Brown AS. Prenatal infection as a risk factor for schizophrenia. Schizophr Bull 2006, 32:200-202. 10.1093/schbul/sbj052, 16469941.
6. Bray TM, Taylor CG. Tissue glutathione, nutrition, and oxidative stress. Can J Physiol Pharmacol 1993, 71:746-751. 10.1139/y93-111, 8313240.
7. Lanté F, Meunier J, Guiramand J, Maurice T, Cavalier M, de Jesus Ferreira M-C, Aimar R, Cohen-Solal C, Vignes M, Barbanel G. Neurodevelopmental damage after prenatal infection: role of oxidative stress in the fetal brain. Free Radic Biol Med 2007, 42:1231-1245. 10.1016/j.freeradbiomed.2007.01.027, 17382204.
8. Wu D, Cederbaum AI. Alcohol, oxidative stress, and free radical damage. Alcohol Res Health 2003, 27:277-284. 15540798.
9. Sies H. Oxidative stress: oxidants and antioxidants. Exp Physiol 1997, 82:291-295. 9129943.
10. Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008, 11:851-876. 18205981.
11. Ranjekar PK, Hinge A, Hegde MV, Ghate M, Kale A, Sitasawad S, Wagh UV, Debsikdar VB, Mahadik SP. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res 2003, 121:109-122. 10.1016/S0165-1781(03)00220-8, 14656446.
12. Mukerjee S, Mahadik SP, Scheffer R, Correnti EE, Kelkar H. Impaired antioxidant defense at the onset of psychosis. Schizophr Res 1996, 19:19-26. 10.1016/0920-9964(95)00048-8, 9147492.
13. Boskovic M, Vovk T, Plesnicar BK, Grabnar I. Oxidative stress in schizophrenia. Curr Neuropharmacol 2011, 9:301-312. 10.2174/157015911795596595, 22131939.
14. Do KQ, Trabesinger AH, Kirsten-Krüger M, Lauer CJ, Dydak U, Hell D, Holsboer F, Boesiger P, Cuénod M. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci 2000, 12:3721-3728. 10.1046/j.1460-9568.2000.00229.x, 11029642.
15. Wang J-F, Shao L, Sun X, Young LT. Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord 2009, 11:523-529. 10.1111/j.1399-5618.2009.00717.x, 19624391.
16. Prabakaran S, Wengenroth M, Lockstone HE, Lilley K, Leweke FM, Bahn S. 2-D DIGE analysis of liver and red blood cells provides further evidence for oxidative stress in schizophrenia. J Proteome Res 2007, 6:141-149. 10.1021/pr060308a, 17203958.
17. Yao JK, Reddy R, McElhinny LG, van Kammen DP. Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr Res 1998, 32:1-8. 10.1016/S0920-9964(98)00030-9, 9690328.
18. Reddy R, Keshavana M, Yao JK. Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr Res 2003, 62:205-212. 10.1016/S0920-9964(02)00407-3, 12837516.
19. Dadheech G, Mishra S, Gautam S, Sharma P. Oxidative stress, α-tocopherol, ascorbic acid and reduced glutathione status in schizophrenics. Indian J Clin Biochem 2006, 21:34-38. 10.1007/BF02912908, 23105610.
20. Akyol O, Herken H, Uz E, Fadillioğlu E, Unal S, Söğüt S, Ozyurt H, Savaş HA. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26:995-1005. 10.1016/S0278-5846(02)00220-8, 12369276.
21. Pavlović D, Tamburić V, Stojanović I, Kocić G, Jevtović T, D{stroke}ord{stroke}ević V. Oxidative stress as marker of positive symptoms in schizophrenia. Facta Univ 2002, 9:157-161.
22. Ben Othmen L, Mechri A, Fendri C, Bost M, Chazot G, Gaha L, Kerkeni A. Altered antioxidant defense system in clinically stable patients with schizophrenia and their unaffected siblings. Prog Neuro-psychopharmacology Bol Psychiatry 2008, 32:155-159. 10.1016/j.pnpbp.2007.08.003.
23. Dietrich-Muszalska A, Olas B, Rabe-Jablonska J. Oxidative stress in blood platelets from schizophrenic patients. Platelets 2005, 16:386-391. 10.1080/09537100500128872, 16236599.
24. Kunz M, Gama CS, Andreazza AC, Salvador M, Ceresér KM, Gomes FA, Belmonte-de-Abreu PS, Berk M, Kapczinski F. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1677-1681. 10.1016/j.pnpbp.2008.07.001, 18657586.
25. Rukmini MS, D'Souza B, D'Souza V. Superoxide dismutase and catalase activities and their correlation with malondialdehyde in schizophrenic patients. Indian J Clin Biochem 2004, 19:114-118. 10.1007/BF02894268, 23105467.
26. Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY. Elevated blood superoxide dismutase in neuroleptic-free schizophrenia: association with positive symptoms. Psychiatry Res 2003, 117:85-88. 10.1016/S0165-1781(02)00303-7, 12581823.
27. Gardiner J, Barton D, Overall R, Marc J: Neurotrophic support and oxidative stress: converging effects in the normal and diseased nervous system. Neurosci 2009, 15:47..
28. Walz JC, Magalhães PV, Giglio LM, Cunha AB, Stertz L, Fries GR, Andreazza AC, Kapczinski F. Increased serum neurotrophin-4/5 levels in bipolar disorder. J Psychiatr Res 2009, 43:721-723. 10.1016/j.jpsychires.2008.10.005, 19081579.
29. Hock C, Heese K, Hulette C, Rosenberg C, Otten U. Region-specific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived Neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch Neurol 2000, 57:846-851. 10.1001/archneur.57.6.846, 10867782.
30. Padurariu M, Ciobica A, Hritcu L, Stoica B, Bild W, Stefanescu C. Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett 2010, 469:6-10. 10.1016/j.neulet.2009.11.033, 19914330.
31. Abeti R, Duchen MR. Activation of PARP by oxidative stress induced by β-amyloid: implications for Alzheimer's disease. Neurochem Res 2012, 37:2589-2596. 10.1007/s11064-012-0895-x, 23076628.
32. Sergi MJ, Rassovsky Y, Widmark C, Reist C, Erhart S, Braff DL, Marder SR, Green MF. Social cognition in schizophrenia: relationships with neurocognition and negative symptoms. Schizophr Res 2007, 90:316-324. 10.1016/j.schres.2006.09.028, 17141477.
33. Brown EC, Tas C, Brüne M. Potential therapeutic avenues to tackle social cognition problems in schizophrenia. Expert Rev Neurother 2012, 12:71-81. 10.1586/ern.11.183, 22149657.
34. Tas C, Danaci AE, Cubukcuoglu Z, Brüne M. Impact of family involvement on social cognition training in clinically stable outpatients with schizophrenia - a randomized pilot study. Psychiatry Res 2012, 195:32-38. 10.1016/j.psychres.2011.07.031, 21831453.
35. Addington J, Addington D. Neurocognitive and social functioning in schizophrenia: a 2.5 year follow-up study. Schizophr Res 2000, 44:47-56. 10.1016/S0920-9964(99)00160-7, 10867311.
36. Couture SM, Granholm EL, Fish SC. A path model investigation of neurocognition, theory of mind, social competence, negative symptoms and real-world functioning in schizophrenia. Schizophr Res 2011, 125:152-160. 10.1016/j.schres.2010.09.020, 20965699.
37. Martínez-Cengotitabengoa M, Mac-Dowell KS, Leza JC, Micó JA, Fernandez M, Echevarría E, Sanjuan J, Elorza J, González-Pinto A. Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes. Schizophr Res 2012, 137:66-72. 10.1016/j.schres.2012.03.004, 22445462.
38. Rijcken CAW, Monster TBM, Brouwers JRBJ, de Jong-van den Berg LTW. Chlorpromazine equivalents versus defined daily doses: how to compare antipsychotic drug doses?. J Clin Psychopharmacol 2003, 23:657-659. 10.1097/01.jcp.0000096247.29231.3a, 14624195.
39. Kroken RA, Johnsen E, Ruud T, Wentzel-Larsen T, Jørgensen HA: Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study. BMC Psychiatry 2009, 9:24..
40. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276. 10.1093/schbul/13.2.261, 3616518.
41. Wechsler D. Wechsler memory scale-third edition 1997, Psychological Corporation, San Antonio, TX.
42. Rey A. L'examen clinique En psychologie 1964, Presses Universitaires de France, Paris.
43. Heaton RK. The Wisconsin card sorting test 1981, Psychological Assessment Resources, Odessa, FL.
44. Benton AL, Hamsher KD, Varney NR, Spreen O. Judgment of line orientation 1983, Oxford University Press, New York.
45. Reitan RM, Wolfson D. The halstead-reitan neuropsycholgical test battery: therapy and clinical interpretation 1985, Neuropsychological Press, Tucson, AZ.
46. Kerr SL, Neale JM. Emotion perception in schizophrenia: specific deficit or further evidence of generalized poor performance?. J Abnorm Psychol 1993, 102:312-318. 10.1037/0021-843X.102.2.312, 8315144.
47. Corcoran R, Mercer G, Frith CD. Schizophrenia, symptomatology and social inference: investigating " theory of mind" in people with schizophrenia. Schizophr Res 1995, 17:5-13. 10.1016/0920-9964(95)00024-G, 8541250.
48. Yilmaz N, Herken H, Cicek HK, Celik A, Yürekli M, Akyol O. Increased levels of nitric oxide, cortisol and adrenomedullin in patients with chronic schizophrenia. Med Princ Pract 2007, 16:137-141. 10.1159/000098367, 17303950.
49. Dietrich-Muszalska A, Olas B, Głowacki R, Bald E. Oxidative/nitrative modifications of plasma proteins and thiols from patients with schizophrenia. Neuropsychobiology 2009, 59:1-7. 10.1159/000202822, 19221441.
50. Arvindakshan M, Ghate M, Ranjekar PK, Evans DR, Mahadik SP. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr Res 2003, 62:195-204. 10.1016/S0920-9964(02)00284-0, 12837515.
51. Akanji AO, Ohaeri JU, Al-Shammri SA, Fatania HR. Associations of blood homocysteine concentrations in Arab schizophrenic patients. Clin Biochem 2007, 40:1026-1031. 10.1016/j.clinbiochem.2007.06.001, 17601525.
52. Applebaum J, Shimon H, Sela B-A, Belmaker RH, Levine J. Homocysteine levels in newly admitted schizophrenic patients. J Psychiatr Res 2004, 38:413-416. 10.1016/j.jpsychires.2004.01.003, 15203293.
53. Dorrell MI, Aguilar E, Jacobson R, Yanes O, Gariano R, Heckenlively J, Banin E, Ramirez GA, Gasmi M, Bird A, Siuzdak G, Friedlander M. Antioxidant or neurotrophic factor treatment preserves function in a mouse model of neovascularization-associated oxidative stress. J Clin Invest 2009, 119:611-623. 10.1172/JCI35977, 19188685.
54. Hayes JD, McLellan LI. Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress. Free Radic Res 1999, 31:273-300. 10.1080/10715769900300851, 10517533.
55. Haque NS, Hlavin ML, Fawcett JW, Dunnett SB. The neurotrophin NT4/5, but not NT3, enhances the efficacy of nigral grafts in a rat model of Parkinson's disease. Brain Res 1996, 712:45-52. 10.1016/0006-8993(95)01427-6, 8705306.
56. Lobner D, Golner S, Hjelmhaug J. Neurotrophic factor effects on oxidative stress-induced neuronal death. Neurochem Res 2003, 28:749-756. 10.1023/A:1022817918651, 12716026.
57. Skaper SD, Floreani M, Negro A, Facci L, Giusti P. Neurotrophins rescue cerebellar granule neurons from oxidative stress-mediated apoptotic death: selective involvement of phosphatidylinositol 3-kinase and the mitogen-activated protein kinase pathway. J Neurochem 1998, 70:1859-1868. 10.1046/j.1471-4159.1998.70051859.x, 9572269.
58. Storz G, Imlay JA. Oxidative stress. Curr Opin Microbiol 1999, 2:188-194. 10.1016/S1369-5274(99)80033-2, 10322176.
59. Lingor P, Unsicker K, Krieglstein K. GDNF and NT-4 protect midbrain dopaminergic neurons from toxic damage by iron and nitric oxide. Exp Neurol 2000, 163:55-62. 10.1006/exnr.2000.7339, 10785444.
60. Lobner D, Liot G. Role of MAPK/ERK in neurotrophin-4 potentiation of necrotic neuronal death. Neurochem Res 2004, 29:2303-2309. 10.1007/s11064-004-7040-4, 15672554.
61. Jarskog LF, Selinger ES, Lieberman JA, Gilmore JH. Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation. Am J Psychiatry 2004, 161:109-115. 10.1176/appi.ajp.161.1.109, 14702258.
62. Jarskog LF, Glantz LA, Gilmore JH, Lieberman JA. Apoptotic mechanisms in the pathophysiology of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:846-858. 10.1016/j.pnpbp.2005.03.010, 15908096.
63. Caron JE, Krull KR, Hockenberry M, Jain N, Kaemingk K, Moore IM. Oxidative stress and executive function in children receiving chemotherapy for acute lymphoblastic leukemia. Pediatr Blood Cancer 2009, 53:551-556. 10.1002/pbc.22128, 19499584.
64. Ryan J, Croft K, Mori T, Wesnes K, Spong J, Downey L, Kure C, Lloyd J, Stough C. An examination of the effects of the antioxidant Pycnogenol on cognitive performance, serum lipid profile, endocrinological and oxidative stress biomarkers in an elderly population. J Psychopharmacol 2008, 22:553-562. 10.1177/0269881108091584, 18701642.
65. Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E. Coenzyme Q10 deficiency in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is related to fatigue, autonomic and neurocognitive symptoms and is another risk factor explaining the early mortality in ME/CFS due to cardiovascular disorder. Neuro Endocrinol Lett 2009, 30:470-476. 20010505.
66. Ramlawi B, Rudolph JL, Mieno S, Khabbaz K, Sodha NR, Boodhwani M, Levkoff SE, Marcantonio ER, Sellke FW. Serologic markers of brain injury and cognitive function after cardiopulmonary bypass. Ann Surg 2006, 244:593-601. 16998368.
67. Flatow J, Buckley P, Miller BJ. Meta-analysis of oxidative stress in schizophrenia. Biol Psychiatry 2013, 74:400-409. 10.1016/j.biopsych.2013.03.018, 23683390.
68. Lysaker PH, Gumley A, Luedtke B, Buck KD, Ringer JM, Olesek K, Kukla M, Leonhardt BL, Popolo R, Dimaggio G. Social cognition and metacognition in schizophrenia: evidence of their independence and linkage with outcomes. Acta Psychiatr Scand 2013, 127:239-247. 10.1111/acps.12012, 22967227.
69. Manoach DS, Gollub RL, Benson ES, Searl MM, Goff DC, Halpern E, Saper CB, Rauch SL. Schizophrenic subjects show aberrant fMRI activation of dorsolateral prefrontal cortex and basal ganglia during working memory performance. Biol Psychiatry 2000, 48:99-109. 10.1016/S0006-3223(00)00227-4, 10903406.
70. Yao JK, Leonard S, Reddy RD. Increased nitric oxide radicals in postmortem brain from patients with schizophrenia. Schizophr Bull 2004, 30:923-934. 10.1093/oxfordjournals.schbul.a007142, 15954198.
71. Gawryluk JW, Wang J-F, Andreazza AC, Shao L, Young LT. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol 2011, 14:123-130. 10.1017/S1461145710000805, 20633320.
72. Brunet-Gouet E, Decety J. Social brain dysfunctions in schizophrenia: a review of neuroimaging studies. Psychiatry Res 2006, 148:75-92. 10.1016/j.pscychresns.2006.05.001, 17088049.
73. Newsome MR, Scheibel RS, Hanten G, Chu Z, Steinberg JL, Hunter JV, Lu H, Vasquez AC, Li X, Lin X, Cook L, Levin HS. Brain activation while thinking about the self from another person's perspective after traumatic brain injury in adolescents. Neuropsychology 2010, 24:139-147. 10.1037/a0017432, 20230107.
74. Isik B, Ceylan A, Isik R. Oxidative stress in smokers and non-smokers. Inhal Toxicol 2007, 19:767-769. 10.1080/08958370701401418, 17613085.
75. Wonisch W, Falk A, Sundl I, Winklhofer-Roob BM, Lindschinger M. Oxidative stress increases continuously with BMI and age with unfavourable profiles in males. Aging Male 2012, 15:159-165. 10.3109/13685538.2012.669436, 22468695.